Palantir's massive run-up is tied to its valuation increasing. Any stock in the market could double under the same circumstances that Palantir's did. Palantir (NASDAQ: PLTR) has been one of the ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...